US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Vyome Holdings, Inc.

2.25

-0.0300-1.32%

Post-market: 2.250.00000.00%16:10 EDT

Volume:5K

Turnover:10.66K

Market Cap:15.79M

PE:-1.40

High:2.30

Open:2.21

Low:2.21

Close:2.28

52wk High:12.00

52wk Low:1.75

Shares:7.02M

Float Shares:1.54M

Volume Ratio:0.38

T/O Rate:0.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6111

EPS(LYR):-4.7480

ROE:-999.17%

ROA:-48.79%

PB:2.61

PE(LYR):-0.47

Loading ...

Overview Company News Filings

Press Release: Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Vyome Holdings Inc. Announces Annual Stockholders Meeting

Vyome Holdings FY 2025 net loss widened to USD 10.48 million as revenue rose 24.43% to USD 319,714

Vyome Subsidiary Livechain Acquires Humanyze Senior Secured Debt in All-Stock Deal

BRIEF-Livechain Completes Acquisition Of Senior, Secured Debt Of Humanyze

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, an Mit Incubated, AI Enabled Hr Analytics Company

THOMSON REUTERS

Press Release: Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Vyome Holdings publishes preclinical VT-1908 data

Vyome publishes positive preclinical uveitis results for VT-1908 eye drops

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/HIND/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HIND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIND\",,,,,undefined,":{"symbol":"HIND","market":"US","secType":"STK","nameCN":"Vyome Holdings, Inc.","latestPrice":2.25,"timestamp":1787342400000,"preClose":2.28,"halted":0,"volume":4688,"hourTrading":{"tag":"盘后","latestPrice":2.25,"preClose":2.25,"latestTime":"16:10 EDT","volume":6,"amount":13.68,"timestamp":1787343004180,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.013157894736842021,"floatShares":1543899,"shares":7018528,"eps":-1.611126,"marketStatus":"Market Closed","change":-0.03,"latestTime":"08-21 16:00:00 EDT","open":2.21,"high":2.3,"low":2.21,"amount":10660,"amplitude":0.039474,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.611126,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1475726400000,"exchange":"NASDAQ","adjPreClose":2.28,"postHourTrading":{"tag":"盘后","latestPrice":2.25,"preClose":2.25,"latestTime":"16:10 EDT","volume":6,"amount":13.68,"timestamp":1787343004180,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.3774678757928943},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIND\",,,,,undefined,":{"symbol":"HIND","floatShares":1543899,"roa":"-48.79%","roe":"-999.17%","lyrEps":-4.747979,"volumeRatio":0.3774678757928943,"shares":7018528,"dividePrice":0,"high":2.3,"amplitude":0.039474,"preClose":2.28,"low":2.21,"week52Low":1.75,"pbRate":"2.61","psRate":"121.73","week52High":12,"institutionHeld":0,"latestPrice":2.25,"eps":-1.611126,"divideRate":0,"volume":4688,"delay":0,"ttmEps":-1.611126,"open":2.21,"prevYearClose":3.44,"prevWeekClose":2.18,"prevMonthClose":2.115,"prevQuarterClose":2.15,"fiveDayClose":2.18,"twentyDayClose":2.06,"sixtyDayClose":2.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HIND\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"HIND","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.1},{"market":"US","date":"2026-06-03","symbol":"HIND","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1780459200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2026-05-12","symbol":"HIND","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2026-03-18","symbol":"HIND","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773806400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-14","symbol":"HIND","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":-3.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HIND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HIND\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1777953600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HIND\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HIND","date":"2026-08-21","current":-1.396539,"percent":0.712,"low":-23.816091,"twenty":-11.259279,"median":-1.558668,"eighty":-1.38689,"high":-0.001601,"avg":-5.443771,"sd":7.427755,"marketCap":16002243},"quantilePoints":[{"date":"2025-08-22","current":-12.854344,"twenty":-12.392244,"median":-11.699095,"eighty":-11.005946,"marketCap":20748595},{"date":"2025-08-29","current":-11.259279,"twenty":-13.22027,"median":-12.854344,"eighty":-11.500884,"marketCap":18173952},{"date":"2025-09-05","current":-9.124707,"twenty":-13.182739,"median":-11.259279,"eighty":-10.03366,"marketCap":14728473},{"date":"2025-09-12","current":-0.001997,"twenty":-12.854344,"median":-10.288753,"eighty":-0.00213,"marketCap":2910},{"date":"2025-09-19","current":-0.001751,"twenty":-12.467306,"median":-9.124707,"eighty":-0.001933,"marketCap":2551},{"date":"2025-09-26","current":-20.664803,"twenty":-13.499407,"median":-10.288753,"eighty":-0.001997,"marketCap":30109879},{"date":"2025-10-03","current":-20.473816,"twenty":-20.473816,"median":-11.259279,"eighty":-0.002098,"marketCap":29831599},{"date":"2025-10-10","current":-21.00858,"twenty":-21.00858,"median":-13.018541,"eighty":-0.002106,"marketCap":30610783},{"date":"2025-10-17","current":-19.327894,"twenty":-20.855791,"median":-13.499407,"eighty":-0.00213,"marketCap":28161920},{"date":"2025-10-24","current":-20.850495,"twenty":-20.850495,"median":-19.346992,"eighty":-0.002143,"marketCap":30380443},{"date":"2025-10-31","current":-21.039016,"twenty":-20.850495,"median":-19.786263,"eighty":-9.124707,"marketCap":30655130},{"date":"2025-11-07","current":-21.340651,"twenty":-21.039016,"median":-20.206435,"eighty":-10.010203,"marketCap":31094630},{"date":"2025-11-14","current":-18.588235,"twenty":-21.00858,"median":-20.168237,"eighty":-10.03366,"marketCap":27084192},{"date":"2025-11-21","current":-17.984966,"twenty":-21.00858,"median":-20.037322,"eighty":-10.543846,"marketCap":26205192},{"date":"2025-11-28","current":-3.129419,"twenty":-20.886349,"median":-19.767164,"eighty":-7.929274,"marketCap":29238478},{"date":"2025-12-05","current":-3.075047,"twenty":-20.851554,"median":-19.327894,"eighty":-3.104045,"marketCap":28730474},{"date":"2025-12-12","current":-2.881724,"twenty":-20.850495,"median":-18.663643,"eighty":-3.026716,"marketCap":26924236},{"date":"2025-12-19","current":-2.342231,"twenty":-20.820331,"median":-18.362009,"eighty":-2.975968,"marketCap":21883703},{"date":"2025-12-26","current":-2.271547,"twenty":-20.790168,"median":-17.381696,"eighty":-2.665444,"marketCap":21223297},{"date":"2026-01-02","current":-2.078224,"twenty":-20.744922,"median":-13.229653,"eighty":-2.363376,"marketCap":19417059},{"date":"2026-01-09","current":-2.072183,"twenty":-20.685727,"median":-12.660825,"eighty":-2.260673,"marketCap":19360614},{"date":"2026-01-16","current":-1.866777,"twenty":-20.618426,"median":-10.790143,"eighty":-2.104806,"marketCap":17441486},{"date":"2026-01-23","current":-1.761053,"twenty":-20.541319,"median":-10.03366,"eighty":-2.062517,"marketCap":16453700},{"date":"2026-01-30","current":-1.292849,"twenty":-20.511156,"median":-6.2932,"eighty":-1.940481,"marketCap":12079217},{"date":"2026-02-06","current":-1.38951,"twenty":-20.503688,"median":-3.129419,"eighty":-1.87886,"marketCap":12982336},{"date":"2026-02-13","current":-1.576792,"twenty":-20.469996,"median":-3.093171,"eighty":-1.729639,"marketCap":14732129},{"date":"2026-02-20","current":-1.661371,"twenty":-20.454717,"median":-3.029737,"eighty":-1.661371,"marketCap":15522358},{"date":"2026-02-27","current":-2.029893,"twenty":-20.435747,"median":-3.008592,"eighty":-1.661371,"marketCap":18965499},{"date":"2026-03-06","current":-1.758033,"twenty":-20.359224,"median":-2.95875,"eighty":-1.667412,"marketCap":16425477},{"date":"2026-03-13","current":-1.4318,"twenty":-20.28493,"median":-2.791104,"eighty":-1.619082,"marketCap":13377450},{"date":"2026-03-20","current":-1.254087,"twenty":-20.244632,"median":-2.425601,"eighty":-1.576792,"marketCap":12869446},{"date":"2026-03-27","current":-1.504653,"twenty":-20.168237,"median":-2.342231,"eighty":-1.56471,"marketCap":15440761},{"date":"2026-04-02","current":-1.470457,"twenty":-20.080611,"median":-2.271547,"eighty":-1.552627,"marketCap":15089835},{"date":"2026-04-10","current":-1.573046,"twenty":-20.054657,"median":-2.19603,"eighty":-1.544169,"marketCap":16142614},{"date":"2026-04-17","current":-1.518332,"twenty":-20.027528,"median":-2.096348,"eighty":-1.529274,"marketCap":15581132},{"date":"2026-04-24","current":-1.545689,"twenty":-19.83321,"median":-2.075203,"eighty":-1.529274,"marketCap":15861873},{"date":"2026-05-01","current":-1.388384,"twenty":-19.755705,"median":-2.0601,"eighty":-1.503285,"marketCap":14247611},{"date":"2026-05-08","current":-1.43626,"twenty":-19.442486,"median":-1.999686,"eighty":-1.470457,"marketCap":14738908},{"date":"2026-05-15","current":-1.232791,"twenty":-19.335533,"median":-1.945315,"eighty":-1.456778,"marketCap":13475573},{"date":"2026-05-22","current":-1.431836,"twenty":-19.175104,"median":-1.918128,"eighty":-1.435375,"marketCap":15651317},{"date":"2026-05-29","current":-1.508885,"twenty":-18.898194,"median":-1.893963,"eighty":-1.43449,"marketCap":16493540},{"date":"2026-06-05","current":-1.476781,"twenty":-18.648562,"median":-1.87886,"eighty":-1.43626,"marketCap":16142614},{"date":"2026-06-12","current":-1.46394,"twenty":-18.475122,"median":-1.845633,"eighty":-1.431822,"marketCap":16002243},{"date":"2026-06-18","current":-1.399732,"twenty":-18.384631,"median":-1.759543,"eighty":-1.421213,"marketCap":15300391},{"date":"2026-06-26","current":-1.354786,"twenty":-18.211192,"median":-1.721785,"eighty":-1.4023,"marketCap":14809094},{"date":"2026-07-02","current":-1.444678,"twenty":-17.864312,"median":-1.691578,"eighty":-1.395484,"marketCap":15791688},{"date":"2026-07-10","current":-1.431836,"twenty":-16.605238,"median":-1.658351,"eighty":-1.395484,"marketCap":15651317},{"date":"2026-07-17","current":-1.406153,"twenty":-13.445456,"median":-1.607243,"eighty":-1.397164,"marketCap":15370576},{"date":"2026-07-24","current":-1.374049,"twenty":-13.22027,"median":-1.588875,"eighty":-1.395224,"marketCap":15019649},{"date":"2026-07-31","current":-1.290579,"twenty":-13.182739,"median":-1.586725,"eighty":-1.393311,"marketCap":14107241},{"date":"2026-08-07","current":-1.374049,"twenty":-12.854344,"median":-1.573046,"eighty":-1.388384,"marketCap":15019649},{"date":"2026-08-14","current":-1.340677,"twenty":-12.467306,"median":-1.565459,"eighty":-1.38689,"marketCap":15160020},{"date":"2026-08-21","current":-1.415158,"twenty":-11.259279,"median":-1.558668,"eighty":-1.38689,"marketCap":16002243}],"updateTime":1787518049543},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HIND\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622852412","title":"Press Release: Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852412","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852412?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:00","pubTimestamp":1774526400,"startTime":"0","endTime":"0","summary":"--  Completed a streamlined Nasdaq listing through a merger transaction,with a common stock capital structure and no preferred stock or debt. --  Delivered positive final Phase 2 results for VT-1953 in treating. symptoms of malignant fungating wounds, in line with expectations. --  Independent valuation consulting firm, Destum Partners, valued VT-1953. at approximately $1 billion after a successful pivotal study. --  Disciplined, cost-efficient operations as Vyome burned less cash than. expected, giving the company a cash runway expected to extend through mid. 2027, taking it up to pivotal trial interim readouts. The Company's lead clinical program, VT-1953, a novel, potential first-in-class topical product targeting symptoms of putrid smell and pain in malignant fungating wounds , which is an inflammatory condition afflicting an estimated one million cancer patients, continued to show strong clinical momentum.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","HIND","VT","BK4588","BK4007","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621918754","title":"Vyome Holdings Inc. Announces Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2621918754","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621918754?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:57","pubTimestamp":1774040265,"startTime":"0","endTime":"0","summary":"Vyome will hold its annual meeting on April 15, 2026 in New York.Shareholders will vote to elect Venkat Nelabhotla and John Tincoff as Class II directors to serve until the 2029 annual meeting.An amendment to reduce authorized common shares to 50,000,000 from 300,000,000 will be submitted for approval.An advisory vote on named executive officer compensation is also scheduled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL1yq4lG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HIND","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232611","title":"Vyome Holdings FY 2025 net loss widened to USD 10.48 million as revenue rose 24.43% to USD 319,714","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232611","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232611?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:40","pubTimestamp":1773830411,"startTime":"0","endTime":"0","summary":"Vyome published its FY 2025 annual report on Form 10-K, reporting revenue of USD 319,714, up 24.43%. FY 2025 net loss widened to USD 10.48 million, while loss from operations was USD 10.45 million. Research and development expense rose more than doubled to USD 588,258 as the company resumed R&D after the merger with new funds raised. General and administrative expense increased more than doubled to USD 2.37 million, driven by higher professional fees tied to the merger and USD 577,128 in stock-based compensation. Vyome said it ended FY 2025 with cash of about USD 4.98 million and expects existing cash plus proceeds from the private placement and its ATM facility to fund operations for at least 15 months, including initiation of a pivotal trial for lead candidate VT-1953.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL7LttYd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4007","HIND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614051341","title":"Vyome Subsidiary Livechain Acquires Humanyze Senior Secured Debt in All-Stock Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2614051341","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614051341?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:33","pubTimestamp":1772055180,"startTime":"0","endTime":"0","summary":"Vyome Holdings Inc. said its subsidiary Livechain, Inc. entered a debt purchase agreement with Remus Capital to acquire a senior, secured convertible note issued by Humanyze. Livechain issued about $325,000 in common stock in exchange and has initiated a default and asset transfer process to assume Humanyze’s business assets and take control of its operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 25, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL6qMs11:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LICH","BK4023","BK4007","HIND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613714872","title":"BRIEF-Livechain Completes Acquisition Of Senior, Secured Debt Of Humanyze","url":"https://stock-news.laohu8.com/highlight/detail?id=2613714872","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613714872?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:16","pubTimestamp":1771938979,"startTime":"0","endTime":"0","summary":"BRIEF-Livechain Completes Acquisition Of Senior, Secured Debt Of HumanyzeFeb 24 (Reuters) - Vyome Holdings Inc HIND.O:LIVECHAIN COMPLETES ACQUISITION OF SENIOR, SECURED DEBT OF HUMANYZE, AN MIT INCUBA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA72SVBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4007","LICH","HIND","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613471161","title":"Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, an Mit Incubated, AI Enabled Hr Analytics Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2613471161","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613471161?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:00","pubTimestamp":1771938006,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA72SVBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4023","BK4007","LICH","BK4082","HIND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613711978","title":"Press Release: Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711978","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613711978?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:00","pubTimestamp":1771938000,"startTime":"0","endTime":"0","summary":"Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026. Livechain, Inc.  , a subsidiary of Vyome Holdings, Inc.  , announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, d/b/a, Humanyze , a rapidly emerging human resources data and analytics company.The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued to Remus by Humanyze. Through this transaction, LICH has initiated a default and asset transfer in order to assume all business assets, including intellectual property and trade secrets, and to take direct control of the daily operations of Humanyze.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIYY","BK4225","BK6062","BK4551","AI","M11.SI","BK4543","HIND","HR","BK4007","BK4528","BK6515","BK4203","BK4082","BK4585","BK4588","MIT","BK4023","BK4587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612441834","title":"Vyome Holdings publishes preclinical VT-1908 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2612441834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612441834?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:11","pubTimestamp":1771423899,"startTime":"0","endTime":"0","summary":"Vyome Holdings (HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vyome-holdings-publishes-preclinical-vt-1908-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vyome-holdings-publishes-preclinical-vt-1908-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","BK4082","HIND","BK4585","VT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612939449","title":"Vyome publishes positive preclinical uveitis results for VT-1908 eye drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2612939449","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612939449?lang=en_us&edition=fundamental","pubTime":"2026-02-18 22:00","pubTimestamp":1771423240,"startTime":"0","endTime":"0","summary":"Vyome Holdings Inc. announced the publication of positive preclinical results for VT-1908, a topical eye-drop candidate for uveitis, in the *Journal of Ophthalmic Inflammation and Infection*. The company reported that VT-1908 achieved target ocular drug concentrations without irritation or signs of toxicity and significantly reduced uveitis scores versus vehicle control in a preclinical model, with efficacy reported as comparable to topical prednisone. Vyome said it intends to advance VT-1908 into clinical development, but no clinical trial start or clinical results were reported in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Bu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDLbfygZd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","BK4082"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":29,"code":"91000000","status":"200"}]}}